CompletedNot Applicable

Growth Differentiation Factor 15 in ICU Acquired Muscle Weakness

Egypt58 participantsStarted 2023-09-10

Plain-language summary

Intensive care unit -acquired weakness (ICU- AW) is a common consequence linked to a worse outcome as evidenced by prolonged mechanical ventilation, longer ICU stays, greater mortality rates and a lower quality of life for survivors, so early detection and treatment of ICU-AW are critical. However, there is no "gold standard" currently available for assessing and diagnosing ICU-AW. It's crucial to develop diagnostic methods that enable for early detection and risk stratification in all critically ill patients, such as: GDF-15 (growth differentiation factor-15) is thought to be a mediator of muscle atrophy because its level increases in the muscular atrophy As a result, measuring GDF-15 seems promise for diagnosing muscle atrophy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age more than 18 conscious patients patients with expected ICU stay more than 7 days Exclusion Criteria: \- unconscious patients spinal cord injury limb fracture or amputations history of cognitive dysfunction severe oedema end stage kidney disease

What they're measuring

Incidence

Timeframe: 1 year

Disease relations

Timeframe: 1 year

Trial details

NCT IDNCT06713746

SponsorMinia University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-09-10

View on ClinicalTrials.gov More Muscle Weakness trials